Lakefront Biotherapeutics traded at 25.72 this Thursday October 1st, decreasing 0.70 or 2.65 percent since the previous trading session. Looking back, over the last four weeks, Lakefront Biotherapeutics lost 3.21 percent. Over the last 12 months, its price fell by 15.39 percent. Looking ahead, we forecast Lakefront Biotherapeutics to be priced at 25.39 by the end of this quarter and at 23.71 in one year, according to Trading Economics global macro models projections and analysts expectations.
Lakefront Biotherapeutics, formerly known as Galapagos NV, is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.